Comparison of commercial hybridization and automated transcription-mediated amplification modalities for detection of high-risk human papillomavirus nucleic acid

Journal of Clinical Microbiology

Volumn 52, Issue 1, 2014, Pages 331-334

  Munson, Erik ^a,b   Kroeger, Lynn ^a   Balzer, Sandra ^a   Amrhein, Robert ^a   Munson, Kimber L ^a   Napierala, Maureen ^a   Hudspeth, Richard ^c   Dillon, Patrick J ^c  

^a Wheaton Franciscan Laboratory   (United States)

^b UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^c AutoGenomics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 68; INTERMETHOD COMPARISON; NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS; YOUNG ADULT;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COINFECTION; FEMALE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NUCLEIC ACID AMPLIFICATION TECHNIQUES; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UNITED STATES; VIROLOGY; YOUNG ADULT;

EID: 84891446433     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03066-13     Document Type: Article

References (23)

1. Lambert PF, Pan H, Pitot HC, Liem A, Jackson M, Griep AE. 1993. Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 90:5583-5587. http://dx.doi.org/10.1073/pnas.90.12 .5583.
2. Czegledy J, Losif C, Hansson BG, Evander M, Gergely L, Wadell G. 1995. Can a test for E6/E7 transcripts of human papillomavirus type 16 serve as a diagnostic tool for the detection of micrometastasis in cervical cancer? Int. J. Cancer 64:211-215. http://dx.doi.org/10.1002/ijc.2910640312.
3. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Halfon P, Ruiz F, Smith JS. 2011. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: The FASE study. Int. J. Cancer 129:691-701. http://dx.doi.org/10.1002/ijc.25726.
4. Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, Gadag V, Holloway G, Bartellas E, Kum N, Giede C, Lear A. 2011. Aptima HPV E6/E7mRNAtest is as sensitive as hybrid capture 2 assay but more specific at detecting cervical precancer and cancer. J. Clin. Microbiol. 49:557-564. http://dx.doi.org/10.1128/JCM.02147-10.
5. Clad A, Reuschenbach M, Weinschenk J, Grote R, Rahmsdorf J, Freudenberg N. 2011. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with hybrid capture 2 and cytology. J. Clin. Microbiol. 49:1071-1076. http://dx.doi.org/10.1128/JCM.01674-10.
6. Stoler MH, Wright TC, Jr, Cuzick J, Dockter J, Reid JL, Getman D, Giachetti C. 2013. APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. Am. J. Obstet. Gynecol. 208:144.e1-144.e8. http://dx.doi.org/10.1016/j .ajog.2012.12.003.
7. Munson E, Du Chateau BK, Nelson BE, Griep J, Czarnecka J, Amrhein RD, Schroeder ER. 2012. Effect of glacial acetic acid treatment of liquidbased cytology collections on performance of Cervista HPV HR for detection of high-risk human papillomavirus. J. Clin. Microbiol. 50:2129-2131. http://dx.doi.org/10.1128/JCM.06719-11.
8. Solomon D, Nayar R (ed). 2004. The Bethesda system for reporting cervical cytology: Definitions, criteria, and explanatory notes, 2nd ed. Springer Verlag, New York, NY.
9. Munson E, Du Chateau BK, Bellerose B, Czarnecka J, Griep J. 2011. Clinical laboratory evaluation of Invader® chemistry and hybrid capture for detection of high-risk human papillomavirus in liquid-based cytology specimens. Diagn. Microbiol. Infect. Dis. 71:230-235. http://dx.doi.org/10.1016/j. diagmicrobio.2011.07.004.
10. Erali M, Pattison DC, Wittwer CT, Petti CA. 2009. Human papillomavirus genotyping using an automated film-based chip array. J. Mol. Diagn. 11:439-445. http://dx.doi.org/10.2353/jmoldx.2009.080154.
11. Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S, Wright C, Lyons D, Szarewski A. 2013. Comparing the performance of six human papillomavirus tests in a screening population. Br. J. Cancer 108:908-913. http://dx.doi.org/10.1038/bjc.2013.22.
12. Du Chateau BK, Schroeder ER, Munson E. 2013. Clinical laboratory experience with Cervista HPV HR as a function of cytological classification: Comparison with retrospective digene HC2 high-risk HPV DNA test data. J. Clin. Microbiol. 51:1057-1058. http://dx.doi.org/10.1128/JCM .02836-12.
13. Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, Reuschenbach M, Belinson S, Belinson JL, Monsonego J. 2013. The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: A meta-analysis of the diagnostic accuracy. Int. J. Cancer 132:101-108. http://dx.doi.org/10.1002/ijc.27636.
14. Ovestad IT, Vennestrøm U, Andersen L, Gudlaugsson E, Munk AC, Malpica A, Feng W, Voorhorst F, Janssen EAM, Baak JPA. 2011. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol. Oncol. 123: 278-283. http://dx.doi.org/10.1016/j. ygyno.2011.07.024.
15. Attoh S, Asmah R, Wiredu EK, Gyasi R, Tettey Y. 2010. Human papilloma virus genotypes in Ghanaian women with cervical carcinoma. East Afr. Med. J. 87:345-349.
16. Zhang J, Yan X, Sun J, Chen Z, Gao Y, Bai Y, Liu Z. 2003. A high throughput assay for human papillomavirus genotypes with fluorescence polarization. Chin. Med. J. (Engl.) 116:1137-1140. http://dx.doi.org/10.1002/ ijc.27636.
17. Giuliani L, Coletti A, Syrjänen K, Favalli C, Ciotti M. 2006. Comparison of DNA sequencing and Roche Linear Array® in human papillomavirus (HPV) genotyping. Anticancer Res. 26:3939-3941.
18. Harvey M, Stout S, Starkey CR, Hendren R, Holt S, Miller GC. 2009. The clinical performance of Invader® technology and SurePath® when detecting the presence of high-risk HPV cervical infection. J. Clin. Virol. 45(Suppl 1): S79-S83. http://dx.doi.org/10.1016/S1386-6532(09)70012-5.
19. Wong AK, Chan RC, Nichols WS, Bose S. 2008. Human papillomavirus (HPV) in atypical squamous cervical cytology: The Invader HPV test as a new screening assay. J. Clin. Microbiol. 46:869-875. http://dx.doi.org/10.1128/JCM.01424-07.
20. Chernesky M, Jang D, Luinstra K, Chong S, Smieja M, Cai W, Hayhoe B, Portillo E, Macritchie C, Main C, Ewert R. 2006. High analytical sensitivity and low rates of inhibition may contribute to detection of Chlamydia trachomatis in significantly more women by the APTIMA Combo 2 assay. J. Clin. Microbiol. 44:400-405. http://dx.doi.org/10.1128/JCM.44 .2.400-405.2006.
21. Ikeda-Dantsuji Y, Konomi I, Nagayama A. 2005. In vitro assessment of the APTIMA Combo 2 assay for the detection of Chlamydia trachomatis using highly purified elementary bodies. J. Med. Microbiol. 54:357-360. http://dx.doi.org/10. 1099/jmm.0.45911-0.
22. Webber H, Stevens L, Ianosie-Irimie M, Jones M. 2012. High-risk human papillomavirus screening of gynecologic specimens: Comparison of the Roche Cobas 4800 with the Hologic Cervista assays, abstr 233. Am. Soc. Clin. Pathol. Annu. Meet., Boston, MA. American Society for Clinical Pathology, Washington, DC.
23. Day SP, Hudson A, Mast A, Sander T, Curtis M, Olson S, Chehak L, Quigley N, Ledford J, Yen-Lieberman B, Kohn D, Quigley DI, Olson M. 2009. Analytical performance of the investigational use only Cervista HPV HR test as determined by a multi-center study. J. Clin. Virol. 45(Suppl 1):S63-S72. http://dx.doi.org/10.1016/S1386-6532(09)70010-1.